BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 30541321)

  • 1. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
    Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
    Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].
    Cao Z; Wang J; Qin N; Li K; Lv J; Wang J; Yang X; Li X; Zhang H; Zhang Q; Long H; Shu C; Ma L; Zhang S
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):84-90. PubMed ID: 32093452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Platform Comparison of Four Leading Technologies for Detecting
    Xu T; Kang X; You X; Dai L; Tian D; Yan W; Yang Y; Xiong H; Liang Z; Zhao GQ; Lin S; Chen KN; Xu G
    Theranostics; 2017; 7(6):1437-1446. PubMed ID: 28529628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
    Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
    Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis.
    Passiglia F; Rizzo S; Rolfo C; Galvano A; Bronte E; Incorvaia L; Listi A; Barraco N; Castiglia M; Calo V; Bazan V; Russo A
    Curr Cancer Drug Targets; 2018; 18(7):697-705. PubMed ID: 29521235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories.
    Ntzifa A; Kroupis C; Haliassos A; Lianidou E
    Clin Chem Lab Med; 2019 Apr; 57(5):e97-e101. PubMed ID: 30267626
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma.
    Veccia A; Girlando S; Dipasquale M; Kinspergher S; Barbareschi M; Caffo O
    J BUON; 2020; 25(2):848-854. PubMed ID: 32521877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays.
    Jiang XW; Liu W; Zhu XY; Xu XX
    Mol Med Rep; 2019 Jul; 20(1):593-603. PubMed ID: 31115577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study.
    Mistry R; Patil A
    Indian J Cancer; 2017 Dec; 54(Supplement):S65-S66. PubMed ID: 29292710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].
    Du J; Wang Z; Yang L; Di J; Zhang JG; Wang TY; Liu DG
    Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):35-39. PubMed ID: 29365415
    [No Abstract]   [Full Text] [Related]  

  • 12. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
    Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
    J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy.
    Filipits M; Kainz V; Sebek V; Zach H; On Behalf Of The Liquid Biopsy Collaborative Study Group
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
    Jensen SG; Epistolio S; Madsen CL; Kyneb MH; Riva A; Paganotti A; Barizzi J; Petersen RK; Børgesen M; Molinari F; Boldorini R; Lorenzen J; Sørensen E; Christensen UB; Høgdall E; Frattini M
    PLoS One; 2021; 16(6):e0253687. PubMed ID: 34166445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Sands J; Li Q; Hornberger J
    Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
    Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
    Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment.
    Bílek O; Holánek M; Berkovcová J; Horký O; Kazda T; Čoupková H; Špelda S; Kristková L; Zvaríková M; Podhorec J; Bořilová S; Bohovicová L; Zdražilová Dubská L
    Klin Onkol; 2019; 32(Supplementum 3):6-12. PubMed ID: 31627700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
    Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
    Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.